Evidence map›Paper›PMID 17823279›Full record

ArticleThe American journal of pathology2007

Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels.

Sudhakar Kalakonda, Shreeram C Nallar, Ping Gong, Daniel J Lindner, Simeon E Goldblum, Sekhar P Reddy, Dhananjaya V Kalvakolanu

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Expression and clinical significance of GRIM-19 in lung cancer.Medical oncology (Northwood, London, England) · 2012
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Sudhakar KalakondaDepartment of Microbiology and Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine, 660 West Redwood St., Howard Hall 350, Baltimore, MD 21201, USA.
Shreeram C Nallar
Ping Gong
Daniel J Lindner
Simeon E Goldblum
Sekhar P Reddy
Dhananjaya V Kalvakolanu
University of Maryland, Baltimore · USCleveland Clinic · USGreen Technology · USJohns Hopkins University · USU-M Rogel Cancer Center

Funding

MODULATION OF IFN ACTION VIA NOVEL REGULATORY FACTORSR01CA078282 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KALVAKOLANU, DHAN V. · 1998 to 2014
$4.4M
Human NRF2 Promoter Functional Polymorphisms and Acute Lung InjuryR01HL066109 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REDDY, SEKHAR P. · 2001 to 2012
$3.5M
The Role and Biology of Fra-1 in Lung Injury and RepairR01ES011863 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REDDY, SEKHAR P. · 2002 to 2013
$3.4M
Cytokine modulated novel growth inhibitory mechanismsR01CA105005 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KALVAKOLANU, DHAN V. · 2004 to 2013
$2.7M
Thrombospondin-1 Opens Endothelial Paracellular Pathway via EGFR/ErbB2 ActivationR01HL084223 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI GOLDBLUM, SIMEON EMANUEL · 2007 to 2011
$1.9M
Inositol hexakisphosphate kinase 2:apoptosis regulatorR01CA095020 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LINDNER, DANIEL J · 2003 to 2006
$1.1M
Fra-1/Nrf2 Balance Signaling and Resolution of Inflammatory Lung InjuryR56ES011863 · NIEHS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REDDY, SEKHAR P. · 2016 to 2016
$90k
NCI NIH HHS CA095020NCI NIH HHS CA105005NCI NIH HHS CA78282NCI NIH HHS R01 CA078282NCI NIH HHS R01 CA095020NCI NIH HHS R01 CA105005NHLBI NIH HHS HL084223NHLBI NIH HHS HL66109NHLBI NIH HHS R01 HL066109NHLBI NIH HHS R01 HL084223NIEHS NIH HHS ES11863NIEHS NIH HHS R01 ES011863NIEHS NIH HHS R56 ES011863
6 · The paper itself

Abstract

Interferons (IFNs) inhibit the growth of infectious pathogens and tumor development. Although IFNs are potent tumor suppressors, they modestly inhibit the growth of some human solid tumors. Their weak activity against such tumors is augmented by co-treatment with differentiation-inducing agents such as retinoids. Previous studies from our laboratory identified a novel gene product, gene associated with retinoid-interferon-induced mortality (GRIM)-19, as an IFN/all-trans retinoic acid-induced growth suppressor. However, the mechanisms of its growth suppressive actions are unclear. The src-family of tyrosine kinases is important regulators of various cell growth responses. Mutational activation of src causes cellular transformation by altering transcription and cytoskeletal properties. In this study, we show that GRIM-19 suppresses src-induced cellular transformation in vitro and in vivo by down-regulating the expression of a number of signal transducer and activator of transcription-3 (STAT3)-dependent cellular genes. In addition, GRIM-19 inhibited the src-induced cell motility and metastasis by suppressing the tyrosyl phosphorylation of focal adhesion kinase, paxillin, E-cadherin, and gamma-catenin. Effects of GRIM-19 on src-induced cellular transformation are reversible in the presence of specific short hairpin RNA, indicating its direct effect on transformation. GRIM-19-mediated inhibition of the src-induced tyrosyl phosphorylation of cellular proteins, such as focal adhesion kinase and paxillin, seems to occur independently of the STAT3 protein. GRIM-19 had no significant effect on the cellular transformation induced by other oncogenes such as myc and Ha-ras. Thus, GRIM-19 not only blocks src-induced gene expression through STAT3 but also the activation of cell adhesion molecules.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosis Regulatory ProteinsCell Adhesion MoleculesCell Line, TumorCell MovementCell Transformation, NeoplasticDown-RegulationGene ExpressionGenes, Tumor SuppressorHumansInterferonsNADH, NADPH OxidoreductasesPhosphorylationRatsRetinoidsApoptosis Regulatory ProteinsCell Adhesion MoleculesInterferonsNADH, NADPH OxidoreductasesNDUFA13 protein, humanRetinoidsRNA, Small Interferingsrc-Family KinasesSTAT3 Transcription FactorTumor Suppressor ProteinsTyrosine

Identifiers

PMID17823279
PMCPMC1988884
OpenAlexW2016680318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.